DailyIQ
|
Last updated1 minute ago

AXSM·Axsome Therapeutics Inc.

$162.27
+5.95 (+3.81%)
After Hours
High
$164.00
Open
$156.68
Market Cap
8.20B
52W High
$261.90
Low
$155.00
P. Close
$162.27
P/E
-
52W Low
$123.42
Fwd P/E
34.33
DailyIQ Est.
$299.76
Inst. Ownership
36.5%
Short Interest
6.31%
Days to Cover
4.4
NewEarnings release, scored · filed Aug 10, 2026tone +0.5 vs prior release · 75 lines scoredSee the breakdown
Technical Score (1D)
93
BULLISH
News Sentiment
50
MIXED
With a Technical Score of 93, Axsome Therapeutics Inc. (AXSM) sits in the upper tier of the momentum ranking on the 1D timeframe. The bullish bias and BUY signal follow from that rank, and trend strength reads as strong. Sentiment at 50 is diverging from the chart. Because the score is relative, it can stay high while the broader market falls, as long as AXSM holds up better than its peers. $148.80 is the near-term risk reference and $165.85 is the next upside marker if buyers keep pressing. DailyIQ's indicator breakdown shows how individual readings such as RSI (oversold) and MACD (bearish) look right now. Those readings are context only and do not feed the Technical Score, which ranks AXSM's momentum against the rest of the universe.
LOW TARGET
$245 +51.0%
2 analysts
MEAN TARGET
$284 +74.8%
5 analysts
HIGH TARGET
$380 +134.3%
23 analysts
PRICE RANGE
$245.00 - $380.00
SB / B / H / S / SS
10/16/2/1/1
DAILYIQ EST.
$299.76 (+84.8%)
Bought (1Y)
0 shares
$0
Sold (1Y)
211,352 shares
$48.9M
Jacobson Mark L.Chief Operating Officer
Option Exercise10,000 shares2026-09-03
Jacobson Mark L.Chief Operating Officer
Sell10,000 shares2026-09-03
Jacobson Mark L.Chief Operating Officer
Option Exercise10,000 shares2026-09-03
TABUTEAU HERRIOTChief Executive Officer
Option Exercise4,660 shares2026-08-06
TABUTEAU HERRIOTChief Executive Officer
Sell4,660 shares2026-08-06
View full insider trading history →
42/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-28.7%
Revenue CAGR
133.7%
Current Ratio
1.55x
Debt / Equity
2.13x
Return on Equity
-207.5%
View full financials →

EPS

EstBeatMiss
$-1.17$-0.99$-0.81$-0.64$-0.46Q2'25Q3'26
QtrEstActual+/−
Q3'26$-0.54 - -
Q2'25$-1.09$-0.97+10.7%

Revenue

EstBeatMiss
$262M$262M$262M$262M$262MQ3'26
QtrEstActual+/−
Q3'26$262M - -
Q2'25 - - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

AXSM Stock Snapshot

BULLISH93/100
$162.22−$0.05 (0.0%)
Market cap
8.20B
Day range
$155.00 – $164.00
News sentiment
50/100 · Neutral
Analyst target
$283.63 (+74.8%)
Consensus
Buy · 30 analysts
52-week range+31.4% off low · -38.1% from high
$123.42$261.90
Price $162.22 DailyIQ Est. $299.76

Trend, momentum and range position line up bullish on AXSM at the moment. At this size, a single catalyst moves the stock further than it would a larger peer.

Sector Rotation

Is money rotating into or out of AXSM's sector?

Axsome Therapeutics Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, AXSM ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for AXSM?

CallsPuts

For Axsome Therapeutics Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 13.07), with at-the-money implied volatility around 69.8%. The options market is pricing roughly a ±4.5% move by that expiry — a range of about $158.53–$173.47.

Put/call ratio (2026-10-16)
13.07
ATM implied volatility
69.8%
Total open interest
3,404
Expected move by 2026-10-16
±4.5% ($158.53–$173.47)

Analyst Rating Changes

Are analysts turning bullish or bearish on AXSM?

RBC Capital most recently reiterated its rating on Axsome Therapeutics Inc. to Outperform on Oct 8, 2026 with a price target of $295 (from $297). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 8, 2026RBC CapitalMaintainedOutperform$297 → $295
Sep 29, 2026Deutsche BankMaintainedBuy$280 → $267
Sep 25, 2026Morgan StanleyMaintainedEqual-Weight$251 → $247
Sep 23, 2026Truist SecuritiesMaintainedBuy$200 → $285
Sep 18, 2026Piper SandlerReiteratedOverweight$258
Aug 31, 2026HC Wainwright & Co.ReiteratedBuy$290
Aug 12, 2026MizuhoMaintainedOutperform$306 → $316
Aug 11, 2026Morgan StanleyMaintainedEqual-Weight$242 → $251
Aug 11, 2026RBC CapitalMaintainedOutperform$304 → $297
Aug 11, 2026GuggenheimMaintainedBuy$260 → $275
Aug 11, 2026Wells FargoMaintainedOverweight$255 → $256
Aug 11, 2026NeedhamMaintainedBuy$267 → $268

Earnings Release, Scored

What did Axsome Therapeutics Inc.'s latest earnings release say?

Filed Aug 10, 2026 · SEC Form 8-K, Exhibit 99

Tone69.0/ 100+0.5 vs prior release
Hedging words1.14per 100 words+0.24 vs prior release
Tone, last 2 releasesScale 50–74

Most important lines

  1. 1

    New-to-brand prescriptions, representing new AUVELITY patient starts, increased 126% among patients ≥65 years of age during the first eight weeks following the Alzheimer’s disease agitation launch compared to the same period in the prior quarter.

    New this quarter
  2. 2

    SYMBRAVO net product sales were $2.3 million for the second quarter of 2026, representing 461% year-over-year growth.

  3. 3

    AUVELITY net product sales were $180.3 million for the second quarter of 2026, representing 51% year-over-year growth.

Scores describe the release's wording. They are not a forecast.

Read all 75 scored lines →

ETF holders

ETFs holding AXSM

Top ETF holdersWeight

News Sentiment Analysis

Sentiment gathered from recent headlines

50/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
The article discusses the future prospects of Axsome Therapeutics as its competitor Auvelity expands into the Alzheimer’s market.
What did this article say?
RBC Capital’s analyst Leonid Timashev reduced Axsome Therapeutics’ price target from $297 to $295, citing modest valuation concerns. The firm retained an Outperform recommendation, indicating confidence in the company’s long‑term prospects. The adjustment reflects a slight downward view on near‑term upside but does not signal a fundamental shift in the business model.
What did this article say?
Axsome Therapeutics reported a 66% revenue increase in FY 2025, driven by the launch of Auvelity for major depressive disorder and Sunosi for narcolepsy, and the upcoming FDA approval of Symbravo for migraine treatment. The company’s strategy includes licensing agreements with Pharmanovia to broaden its European and Middle Eastern presence. These developments reinforce Axsome’s position as a focused neuroscience player with a growing product pipeline and expanding market reach.
What did this article say?
On Oct. 7, 2026, Axsome Therapeutics announced it would report its third‑quarter 2026 financial results on Nov. 2, 2026, and would hold a conference call at 8:00 a.m. Eastern Time to discuss the results and provide a business update. The company provided contact information for the live call and noted that a webcast would be available on its website. A replay of the call would be accessible for approximately 30 days after the event.
What did this article say?
Baird Equity Asset Management released its Q2 2026 investor letter, noting a sharp rebound in the broader equity market driven by AI investment and resilient earnings. The letter highlighted that while the overall growth strategy underperformed the Russell 2500 Growth Index, it still delivered 17.7% net of fees. Baird identified AI as a long‑term value driver and expressed optimism for AXSM’s growth potential within the healthcare sector, despite the sector’s relative underperformance during the quarter.
What did this article say?
Axsome Therapeutics reported a 65.5% revenue increase to $638.5 million in FY2025, driven by its approved CNS products Auvelity and Sunosi. The company settled Sunosi patent litigation, establishing a framework for generic entry in 2040, which provides long‑term clarity for that product line. Compared to Vertex Pharmaceuticals, Axsome presents a higher growth trajectory but lower cash‑flow maturity, making it an attractive high‑risk, high‑reward biotech option for investors seeking expansion in central nervous system disorders.
What did this article say?
Deutsche Bank analyst David Hoang kept a buy rating on Axsome Therapeutics (NASDAQ:AXSM) but reduced the price target from $280 to $267. The adjustment reflects a reassessment of the company’s valuation. The rating remains positive, though the lower target signals a modest headwind for the stock.
What did this article say?
Morgan Stanley analyst Sean Laaman reduced Axsome Therapeutics’ price target from $251 to $247 while keeping the stock on an equal‑weight recommendation. The downgrade reflects concerns over the company’s valuation relative to peers and the lack of recent upside catalysts. The firm’s assessment suggests that the current market price may be slightly overvalued, but no immediate negative catalysts were identified.
What did this article say?
Axsome Therapeutics (NASDAQ:AXSM) delivered an annualized return of 37.87% over the past decade, outperforming the broader market by 24.39%. The company’s share price has risen steadily, reflecting investor confidence in its pipeline and management. No new product approvals or regulatory changes were reported in the article, so the performance is presented as historical context rather than a catalyst for future moves.

Technical Analysis

Real-time indicators across multiple timeframes

93
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $4.29B combined position · 11 adding, 14 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▼ Sell4,164,8187.95%$760.66M2026-01-29
BlackRock, Inc.▼ Sell3,103,7085.92%$759.69M2026-08-07
Invesco Ltd.▲ Buy1,671,6843.19%$409.18M2026-08-14
FMR LLC (Fidelity)▼ Sell1,539,1632.94%$376.74M2026-08-13
Geode Capital Management, LLC▼ Sell967,1721.85%$236.79M2026-08-12
Morgan Stanley▲ Buy804,0821.53%$196.82M2026-08-13
Two Sigma Investments, LP▲ Buy669,4781.28%$163.87M2026-08-14
Wellington Management Group LLP▼ Sell653,9201.25%$160.06M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy604,7531.15%$148.03M2026-08-14
Millennium Management LLC▲ Buy556,0881.06%$136.11M2026-08-14
Norges Bank▲ Buy514,2660.98%$125.88M2026-08-12
Bank of America Corp▼ Sell452,4910.86%$110.76M2026-08-14
Point72 Asset Management, L.P.▼ Sell416,5160.79%$101.95M2026-08-14
Northern Trust Corp▼ Sell270,1890.52%$66.13M2026-08-13
Renaissance Technologies LLC▲ Buy262,0000.50%$64.13M2026-08-13
Adage Capital Partners GP, L.L.C.▼ Sell259,0340.49%$63.40M2026-08-14
Citadel Advisors LLC▼ Sell255,8780.49%$62.63M2026-09-02
Loomis Sayles & Co L P▼ Sell239,4900.46%$58.62M2026-08-14
Goldman Sachs Group Inc▼ Sell229,6680.44%$56.22M2026-08-14
Marshall Wace, LLP▲ Buy223,3860.43%$54.68M2026-08-13
JPMorgan Chase & Co▼ Sell162,0650.31%$39.55M2026-08-12
Neuberger Berman Group LLC▲ Buy156,5230.30%$38.31M2026-08-13
Squarepoint Ops LLC▲ Buy154,6050.29%$37.84M2026-08-14
Citigroup Inc▼ Sell136,8580.26%$33.50M2026-08-03
AQR Capital Management LLC▲ Buy114,0250.22%$27.91M2026-08-14
Q2 2026 flow:1.93M sh bought ($472.31M)2.68M sh sold ($655.73M)net -749.6K sh (−$183.42M)
View full institutional holdings history →

Discover More

DHR
Danaher Corporation
$224.69
+0.00%
USMV
iShares MSCI USA Min Vol Factor ETF
$100.63
-0.01%
APGE
Apogee Therapeutics Inc.
$135.11
+0.01%
BSX
Boston Scientific Corporation
$42.90
-0.26%
NBIX
Neurocrine Biosciences Inc.
$135.50
-0.31%
XLV
Health Care Select Sector SPDR Fund
$173.90
-0.02%
JNJ
Johnson & Johnson
$253.89
-0.02%
MDGL
Madrigal Pharmaceuticals Inc.
$460.01
+0.06%
GEHC
GE HealthCare Technologies Inc.
$68.43
-0.07%
CYTK
Cytokinetics Incorporated
$63.43
-0.02%